Nitroglycerin as Spasmolytic Regimen for RAS Prevention in Radial Center — NORAS  

Radial Artery Injury Clinical Trial

Official title: A Randomized Comparison of Nitroglycerin Versus Placebo as Spasmolytic Regimen to Prevent Moderate to Severe Radial Artery Spasm in Radial Center

Status Recruiting

Clinical Trial Summary

The investigators will investigate whether administration of Nitroglycerin (NTG) as spasmolytic regimen reduces the incidence of moderate to severe radial artery spasm (RAS) in patients undergoing transradial catheterization in radial center.

Clinical Trial Description

Patients will be randomized to receive either 200 microgram NTG or placebo (saline) at the beginning of the procedure soon after radial sheath placement. The operators will be blinded to both assignment. The primary outcome is the incidence of moderate to severe RAS evaluated by the operators during the radial procedure.

Both NTG and placebo will be administered using an identical syringe to keep the operators blinded to the treatment allocation. Radial angiogram is mandatory to measure the diameter of both radial and ulnar arteries. Doppler ultrasound of the radial artery will be examined at the day after the procedure. ;

Related Conditions & MeSH terms

• Radial Artery Injury

• NCT number: NCT03889470
• Study type: Interventional
• Source: Hermina Heart Center Kemayoran
• Contact: Agnes Intan, MD
• Phone: 622122608047
• Email: agnesintan1231@gmail.com
• Status: Recruiting
• Phase: Phase 4
• Start date: March 31, 2018
• Completion date: October 1, 2019